Expert Details
Life Sciences with focus on Cancer Immunology, Assay Development and Bioanalytics
ID: 737766
Germany
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 2008 | Degree: Diploma | Subject: Biology | Institution: Technical University Kaiserslautern, Germany |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2020 to Present | Employer: Undisclosed | Title: Head of Assay Development and Bioanalytics | Department: Assay Development and Bioanalytics |
Responsibilities:Steer all day-to-day operations of the Assay Development department. Provide services to technical personnel as Line Manager. Formulate and deliver comprehensive reports to management ensuring informed decision making. Deliver effective technical support to develop new assays and to implement current methodologies. Support onboarding of two new team members. Formulate comprehensive study reports and presentations.● Create CoAs while administering analytics pertaining to CGE, HPLC, biological activity and HCP for in-house generated proteins. ● Plan, write and review pre-clinical study plans and reports as well as support analytics for clinical studies. |
|||
| Years | Employer | Title | Department |
| Years: 2018 to 2020 | Employer: Apogenix AG | Title: Laboratory Manager Assay Development and Bioanalytics | Department: Assay Development and Bioanalytics |
Responsibilities:Formulated and optimized biochemical/cellular assays such as PK-analytics, ADA, nAbs, and cytokines. Transferred internally designed assays to CROs which subsequently performed the assays under GLP-conditions; analysed data sent back by the CROs. Represented Apogenix on several international conferences, including AACR, World Immune Regulation Meeting and Festival of Biological to increase visibility of products to scientific or commercial partners.● Created CoAs while administering analytics pertaining to CGE, HPLC, biological activity, and HCP for in-house generated proteins. ● Developed three different products from the pre-clinical status to a ready-to-go IND. ● Analysed pre-clinical study plans and reports as well as supported analytics for clinical studies. |
|||
| Years | Employer | Title | Department |
| Years: 2014 to 2018 | Employer: BioMed X Innovation Center | Title: Senior Scientist (Postdoc) | Department: Research group "Immunosuppressive Microenvironment of Tumors" |
Responsibilities:Conducted phenotypic and functional analysis of immune cells (MDSC, DC) with FACS, ELISA and microscopy. Oversaw the preparation of cells/tissue, isolated RNA/DNA, performed RNA-sequencing and interpreted the generated results thereof. Executed all end-to-end operations of internal and external results ranging from analysis, interpretation to presentation. Performed high-throughput screening assays with primary myeloid cells and tumour cell lines.● Led and optimised personal competencies of one technician and two research associates. ● Achieved desired results through effective planning and supervision of experiments. ● Established lab from scratch by ordering new machines and lab material as well as setting up all new techniques |
|||
| Years | Employer | Title | Department |
| Years: 2011 to 2014 | Employer: University Clinic of Bonn | Title: Senior Scientist (Postdoc) | Department: Experimental Immunology |
Responsibilities:Collaborated with Evonik and Merck KGaA to formulate nanoparticulate carrier for varied applications. Managed a team comprised of one technician and one research associate to accomplish targeted research. Planned, executed, and supervised experiments while performing pharmacodynamic / -kinetic analyses in mice. Delivered exceptional results, resulting in securing a patent with Merck and winning the Nanomedicine Award 2015.● Utilised FACS and microscopy for in-depth analysis of the nanoparticle uptake mechanism. ● Optimised coating of nanoparticles to increase their intake in different cell types including macrophages, T cells, B cells and tumor cell lines by nanoparticle formulations screening |
|||
| Years | Employer | Title | Department |
| Years: 2008 to 2011 | Employer: University Clinic of Frankfurt am Main | Title: PhD Student | Department: Immunepharmacology |
Responsibilities:During my Ph.D. phase I investigated the impact of sphingosine kinases on activation and development of dendritic cells. I worked with transgenic mice, used basic and advanced immunological techniques and established a detection method with LC-ESI-MS/MS in a cooperation. |
|||
Career Accomplishments
| Licenses / Certifications |
|---|
| Preclinic compact. FORUM Institute for management GmbH. June 2021 FELASA B Zertifikat (animal experiment qualification) Since September 2009. IATA certificate March 2021 ECA certified Biotech Manager. ECA Academy. Sept. 2019 |
| Professional Appointments |
|---|
| PhD student at the Universitiy Clinic of Frankfurt am Main Senior Scientist at the University Clinic of Bonn Senior Scientist at BioMed X Innovation Center, Heidelberg Laboratory Manager Assay Development and Bioanalytics at Employer, Heidelberg Head of Assay Development and Bioanalytics at Employer, Heidelberg |
| Awards / Recognition |
|---|
| Nanomedicine Award 2015 for the Best Nanomedicine Early Clinical Stage Project - "Inhalable chitosan-based nano-in-microparticles for mucosal therapeutic vaccination |
| Publications and Patents Summary |
|---|
| 1 Patent: Antigen-loaded chitosan nanoparticles for immunotherapyAntigen-loaded chitosan nanoparticles for immunotherapy DE WO/2015/185180 The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination. 13 Publications in total: The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleenThe sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen Molecular Immunology · 1. Mai 2011 LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci · 30. Jan. 2012 CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activationCXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation Journal of Immunology · 1. Apr. 2013 The role of the Tra1p transcription factor of Magnaporthe oryzae in spore adhesion and pathogenic developmentThe role of the Tra1p transcription factor of Magnaporthe oryzae in spore adhesion and pathogenic development Fungal Genet Biol · 31. Mai 2013 Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells. Scand J Immunol · 1. Dez. 2014 Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application. Biol. Chem. · 1. Juni 2015 Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunityAntigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity European Journal of Pharmaceutics and Biopharmaceutics · 1. März 2016 Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening / Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening Oncoimmunology · 1. Jan. 2017 The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent. Scientific Reports · 20. Dez. 2017 Sortaggable liposomes: Evaluation of reaction conditions for single-domain antibody conjugation by Sortase-A and targeting of CD11b+ myeloid cellsSortaggable liposomes: Evaluation of reaction conditions for single-domain antibody conjugation by Sortase-A and targeting of CD11b+ myeloid cells European Journal of Pharmaceutics and Biopharmaceutics · 1. Sept. 2018 Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation.Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation. Scientific Reports · 7. Sept. 2018 Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells.Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells. Eur J Pharm Biopharm. · 20. Nov. 2018 HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionalityHERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality Jurnal for Immunotherapy of Cancer · 1. Aug. 2019 |
Additional Experience
| Expert Witness Experience |
|---|
| https://www.everydays.de/pages/dr-Expert-schroeder https://crispr-bte.com/course-and-certification-program/ |
Language Skills
| Language | Proficiency |
|---|---|
| German | Native |
| English | Fluent |